Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-19-039127
Filing Date
2019-06-26
Accepted
2019-06-26 16:55:44
Documents
1
Period of Report
2019-06-24

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 14049
  Complete submission text file 0001209191-19-039127.txt   15417
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address
GORDON CARL L (Reporting) CIK: 0001282930 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38939 | Film No.: 19922233

Mailing Address 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016
Business Address 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016 917-336-9310
Prevail Therapeutics Inc. (Issuer) CIK: 0001714798 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)